TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07923214: A Phase I, Open-Label, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CG-7321 as Monotherapy or in Combination Therapy in Subjects With Advanced Solid Tumors

Sponsor: Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 30 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,100,016

Rescue Site Savings

+$4,680,984

Unlock Full NCT07923214 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07923214 Rescue Dossier →